Optometrists Will Be Crucial Marketing Target For Shire’s Lifitegrast
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory approval remains the primary challenge with the dry-eye candidate, but Shire is also thinking ahead to a potentially big opportunity to offer a therapeutic improvement compared to Restasis.